According to FutureWise analysis, the Corneal Endothelial Cell Transplant market in 2025 is US$347.06 million, and is expected to reach US$672.13 million by 2033 at a CAGR of 8.61%. The significant growth in the market is primarily driven by the increasing prevalence of corneal disorders, such as keratoconus, corneal scarring, and Fuchs' dystrophy. These conditions affect millions of people worldwide and necessitate specialized endothelial transplantation procedures. Market expansion is further fueled by advancements in surgical techniques and the aging global population, which contributes to a rise in age-related corneal conditions. Additionally, the growing awareness and acceptance of eye donation programs help to alleviate the critical shortage of donor corneal tissue. In 2023, the Corneal Endothelial Cell Transplant market was valued at $303.2 million and is projected to reach $630 million by 2031, with a compound annual growth rate (CAGR) of 9.30%. This growth is attributed to the rising prevalence of corneal disorders, advancements in transplantation techniques, technological developments in ophthalmology, increased awareness of eye health, and supportive healthcare policies.

Clinical Advancements: Recent studies have demonstrated that the use of cultured human corneal endothelial cells is a safe and effective long-term treatment for corneal endothelial dysfunction. This method aims to address the shortage of donor corneas and provides a sustainable solution for patients experiencing endothelial cell loss.

A corneal transplant is a surgical procedure for replacing a damaged or diseased cornea that may have developed as a result of an eye injury or an underlying eye condition. The two most common transplant procedures worldwide are penetrating keratoplasty (a full-thickness cornea transplant) and endothelial keratoplasty (a transplant of the back layer of the cornea). Vision blurring due to a sick cornea indicates the need for a corneal transplant.

The monolayer of cells that forms the human corneal endothelium is essential for maintaining corneal transparency and is not known to regenerate naturally in the body. As a result, the approximately 150,000 corneal transplants performed each year are mainly due to the dysfunction of these cells. Although current corneal transplantation has a success rate of over 90% within the first year, the long-term outcomes are less promising, with only about a 70% success rate after five years. The primary challenges include non-immunologic graft failure and allograft endothelial rejection. Additionally, the severe shortage of corneal donors limits the number of transplants that can be performed. However, recent advances in our understanding of corneal endothelial cell biology have made it possible to grow human corneal endothelial cells (HCECs) in vitro, which opens new avenues for developing novel tissue-engineered human corneal endothelium.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Corneal Endothelial Cell Transplant Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=15193&type=requestsample

By Techniques

• Descemet Stripping Endothelial Keratoplasty (DSEK)
• Deep Lamellar Endothelial Keratoplasty (DLEK)
• Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
• Descemet Membrane Endothelial Keratoplasty (DMEK)
• Pre-Descemet Endothelial Keratoplasty (PDEK)
• Descemetorhexis without Endothelial Keratoplasty (DWEK)
• Descemet Stripping Only (DSO)
• Descemet Membrane Endothelial Transfer (DMET)

By Indications

• Fuchs dystrophy
• Fungal Corneal Ulcer
• Keratoconus
• Keratitis
• Acquired Pseudophakic
• Bullous keratopathy
• Iridocorneal endothelial syndrome
• Corneal Stromal Dystrophies
• Postinfective Keratitis
• Other Indications

By End-User

• Hospitals
• Eye Clinic
• Ambulatory Surgical Centers

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Here’s a regional view of where the most progress is happening:

Asia Pacific

• The region is expected to be the fastest-growing, with a projected market share of 29.8% by 2025.
• India: There will be a strong emphasis on improving the infrastructure for corneal transplantation to achieve one lakh eye donations each year by 2030.
• China: Substantial investments are being made in healthcare infrastructure, accompanied by an increasing awareness of the importance of eye health.

Competitive Landscape in Corneal Endothelial Cell Transplant Market:

• Ajl Ophthalmic SA
• Exactech, Inc.
• Keramed Inc.
• Lifeline Scientific
• CorneaGen
• Corneat Vision
• CryoLife Inc.
• Kohler GmbH
• Lifecell Corporation
• Medtronic plc.
• Organogenesis Inc.
• Presbia plc.

Recent developments by key players in the Corneal Endothelial Cell Transplant Market:

AJL Ophthalmic SA

• In October 2024, AJL unveiled the groundbreaking ENDO-K PRO, a revolutionary corneal implant set to transform the landscape of keratoconus surgery and deep anterior lamellar keratoplasty (DALK). This innovative device promises to significantly improve patient outcomes, offering hope and enhanced vision for those undergoing these procedures. Prepare to experience a new era in corneal care!
• The ENDO-K PRO intercorneal implant is a PMMA-based device designed for complex cases that are typically not suitable for penetrating keratoplasty. It comes in various ring diameters, ranging from 7.5 to 9 mm, and provides structural support for eyes with severe corneal edema or other vision-threatening conditions. This implant offers a tailored surgical option for challenging situations.

  CorneaGen

• In June 2024, CorneaGen introduced Corneal Tissue Addition for Keratoplasty (CTAK), a solution designed to enhance patient outcomes in keratoplasty procedures.
• We are actively developing a cornea cell therapy platform that focuses on culturing and injecting corneal endothelial cells derived from a single donor cornea, providing sufficient cells for over 100 treatments. Early clinical results in Japan have shown that corneal clarity can be maintained for 4 to 5 years after injection. We are currently seeking regulatory approval in Japan, followed by the United States.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=15193&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Corneal Endothelial Cell Transplant Market By Techniques, By Indications, By End-User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com